Status:
UNKNOWN
Annexin A3 (ANXA3) as Protein-Based Marker for Non-Invasive Molecular Diagnostics of Prostate Carcinoma
Lead Sponsor:
ProteoSys AG
Collaborating Sponsors:
Charite University, Berlin, Germany
University Hospital Tuebingen
Conditions:
Prostate Cancer
Benign Prostatic Hyperplasia
Eligibility:
MALE
Brief Summary
Emerging from a differential proteomic study of sample pairs of prostate cancer and benign tissue, annexin A3 (ANXA3) was chosen as a potential novel biomarker for the early and non-invasive diagnosis...
Detailed Description
The aim of this multi centre and double-blinded study was to investigate specificities and sensitivities of early detection of prostate cancer with a new protein biomarker, annexin A3, using urine aft...
Eligibility Criteria
Inclusion
- Patients with a histological confirmation of adenocarcinoma of the prostate
- Patients with benign prostatic hyperplasia (confirmed by histology of lance biopsies or TUR-P)
Exclusion
- Patients with rectal extirpation
- Patients with renal or bladder tumors
Key Trial Info
Start Date :
September 1 2005
Trial Type :
OBSERVATIONAL
End Date :
September 1 2006
Estimated Enrollment :
750 Patients enrolled
Trial Details
Trial ID
NCT00400894
Start Date
September 1 2005
End Date
September 1 2006
Last Update
February 5 2007
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.